Pegasys/Copegus effective in non-responders
Pegasys/Copegus effective in non-responders
Cure rates for certain groups of difficult-to-treat hepatitis C patients can be improved significantly by extending the treatment period with Pegasys (peginterferon alfa-2a (40KD)) and Copegus (ribavirin) to 72 weeks, according to the maker of the drugs, Roche.
The Swiss drug major says that treatment-naive genotype-1 or -4 patients with undetectable hepatitis C virus in the blood after four weeks of treatment (RVR) but with an early virological response (EVR) by week 12 have a better chance for a cure, and less likelihood of relapse, by extending the treatment duration to 72 weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze